Value
6.0/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 4.5 |
| Fwd P/E | 6.2 |
| PEG | 10.0 |
| Analyst target | 5.0 |
- ▸Forward P/E: 21.0x
- ▸PEG: 0.15
HNGE · Why this verdict
Why Hinge Health (HNGE) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.1/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
An elite-growth healthcare technology business generating exceptional free cash flow despite GAAP losses, with four consecutive earnings beats and 47% revenue growth — but the stock has effectively reached the analyst consensus target, leaving thin upside and an 82% partner contract concentration that warrants caution at current prices.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Despite reporting GAAP losses, the company generated a free cash flow margin of 69% and a free cash flow yield of 8.4%; a combined growth-and-margin score of 116 on the Rule of 40 reflects a rare level of operating leverage for a company at this growth stage. Quality breakdown | Free cash flow margin stays above 50% and the Rule of 40 score remains above 80 over the next four quarters, confirming the high-quality cash engine is not a one-period result. | →Stable |
| CounterFCF margin in fast-growth software businesses can be volatile; high deferred revenue or aggressive capitalization can flatter near-term cash conversion while the underlying cost structure continues to scale. | ||
With roughly 82% of revenue tied to partner contracts, the business faces a structural single-point-of-failure risk; a renegotiation, non-renewal, or pricing adjustment from a key partner could disproportionately impair revenue. Bear case | Partner contract concentration falls below 70% of total revenue over the next 12 months, indicating meaningful diversification of the revenue base. | →Stable |
| CounterHigh partner concentration in healthcare services often reflects deep integration and elevated switching costs, which can be a sign of durable, sticky relationships rather than fragility. | ||
Revenue growth of 47% year-over-year places the company at the top of its peer group as an industry growth leader, and strong earnings growth reinforces that scale is being achieved without deteriorating unit economics. Growth breakdown | Revenue growth stays above 30% year-over-year for at least 2 consecutive quarters, demonstrating the hypergrowth trajectory is not decelerating to a commoditized rate. | →Stable |
| CounterHigh-growth healthcare technology companies carry concentration risk; with partner contracts representing 82% of revenue, a single large-partner renegotiation or churn event could cause reported growth to decelerate sharply. | ||
Four consecutive quarterly earnings beats — with the most recent at 13% above consensus and an earlier quarter delivering a surprise exceeding 700% — reflect a pattern of consistently delivering ahead of expectations across multiple reporting cycles. Earnings | The company delivers a fifth consecutive earnings beat of at least 5% at the next quarterly report, extending the track record of execution. | →Stable |
| CounterA string of large positive surprises typically compresses future upside as analysts reset expectations higher; the next beat hurdle is materially higher than when the streak began, increasing the risk of an in-line or minor miss. | ||
Despite reporting GAAP losses, the company generated a free cash flow margin of 69% and a free cash flow yield of 8.4%; a combined growth-and-margin score of 116 on the Rule of 40 reflects a rare level of operating leverage for a company at this growth stage.
→StableQuality breakdown
- Expectation
- Free cash flow margin stays above 50% and the Rule of 40 score remains above 80 over the next four quarters, confirming the high-quality cash engine is not a one-period result.
CounterFCF margin in fast-growth software businesses can be volatile; high deferred revenue or aggressive capitalization can flatter near-term cash conversion while the underlying cost structure continues to scale.
With roughly 82% of revenue tied to partner contracts, the business faces a structural single-point-of-failure risk; a renegotiation, non-renewal, or pricing adjustment from a key partner could disproportionately impair revenue.
→StableBear case
- Expectation
- Partner contract concentration falls below 70% of total revenue over the next 12 months, indicating meaningful diversification of the revenue base.
CounterHigh partner concentration in healthcare services often reflects deep integration and elevated switching costs, which can be a sign of durable, sticky relationships rather than fragility.
Revenue growth of 47% year-over-year places the company at the top of its peer group as an industry growth leader, and strong earnings growth reinforces that scale is being achieved without deteriorating unit economics.
→StableGrowth breakdown
- Expectation
- Revenue growth stays above 30% year-over-year for at least 2 consecutive quarters, demonstrating the hypergrowth trajectory is not decelerating to a commoditized rate.
CounterHigh-growth healthcare technology companies carry concentration risk; with partner contracts representing 82% of revenue, a single large-partner renegotiation or churn event could cause reported growth to decelerate sharply.
Four consecutive quarterly earnings beats — with the most recent at 13% above consensus and an earlier quarter delivering a surprise exceeding 700% — reflect a pattern of consistently delivering ahead of expectations across multiple reporting cycles.
→StableEarnings
- Expectation
- The company delivers a fifth consecutive earnings beat of at least 5% at the next quarterly report, extending the track record of execution.
CounterA string of large positive surprises typically compresses future upside as analysts reset expectations higher; the next beat hurdle is materially higher than when the streak began, increasing the risk of an in-line or minor miss.
Per-dimension breakdown
Quality
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 7.0 |
| Net margin | 0.0 |
| Current ratio | 4.9 |
| FCF quality | 10.0 |
| Moat | 5.8 |
| Rule of 40 | 9.5 |
| Piotroski F | 5.6 |
- ▸FCF-positive despite GAAP loss (FCF margin 69%, FCF yield 8.2%)
- ▸Rule of 40: 116 (elite)
Growth
10.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 10.0 |
- ▸Strong growth: 47% YoY
Momentum
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.1 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 78)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 8.5 |
| Analyst rating | 7.3 |
| Price target | 6.6 |
- ▸LLM news sentiment: +0.70 (n=1)
Insider
3.1/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.0 |
| holder change | 5.4 |
- ▸Heavy insider selling — $31,046,726 (0.569% of mkt cap)
Peer rank
3.3/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 0.8 |
| quality rank | 0.0 |
| growth rank | 9.2 |
- ▸Industry growth leader
Technical
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.3 |
| support resistance | 0.5 |
| 52w position | 9.8 |
Risk (lower is worse)
5.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.2 |
| days to cover | 8.6 |
| volatility | 0.5 |
| put call | 10.0 |
| implied vol | 4.5 |
| max pain risk | 3.0 |
| debt equity | 2.8 |
- ▸Above max pain $30
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 5.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING).
Engine technical detail
verdict_path:
L4:PATH_F_SELL|L3:NEWS_MOD=+2Passed (6)
- MOMENTUM:6.6>=5.5
- INSIDER:OK
- NEWS_BOOST:ANALYST:0.70
- EARNINGS_PROXIMITY:40d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.0<1.5@spot
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.01
Upside
+0.1%
Downside
15.0%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityMODERATE — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 4.6 below the 5.4 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Growth at 10.0) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:0.0<1.5@spot) reinforce the read. Current asymmetry R:R is 0.01 — supplementary context, not the trigger for this path.
The strongest dimensions are Growth at 10.0, Sentiment at 7.5, and Catalyst at 7.0; the weakest are Insider at 3.1, Peer rank at 3.3, and Technical at 3.9. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 0.01 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Despite reporting GAAP losses, the company generated a free cash flow margin of 69% and a free cash flow yield of 8.4%; a combined growth-and-margin score of 116 on the Rule of 40 reflects a rare level of operating leverage for a company at this growth stage.
Trip ifFree cash flow margin falls below 40% for 2 consecutive quarters.
- P2Revenue growth of 47% year-over-year places the company at the top of its peer group as an industry growth leader, and strong earnings growth reinforces that scale is being achieved without deteriorating unit economics.
Trip ifRevenue growth falls below 25% year-over-year for 2 consecutive quarters.
- P3Four consecutive quarterly earnings beats — with the most recent at 13% above consensus and an earlier quarter delivering a surprise exceeding 700% — reflect a pattern of consistently delivering ahead of expectations across multiple reporting cycles.
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P4With roughly 82% of revenue tied to partner contracts, the business faces a structural single-point-of-failure risk; a renegotiation, non-renewal, or pricing adjustment from a key partner could disproportionately impair revenue.
Trip ifPartner contract concentration falls below 65% of total revenue for 2 consecutive quarters.